



Strategic Partnership Announcement

KBI Biopharma + MilliporeSigma Advance Cytotoxic ADC Manufacturing

KBI Biopharma and MilliporeSigma have partnered to provide integrated end-to-end solutions for ADCs, combining expertise in process development, mAb intermediate manufacturing, bioconjugation, and bulk drug substance production.

KBI's Capabilities

- ✓ Extensive tenure of manufacturing first-in-human through commercial antibody products, including robust process development and optimization
- ✓ Respective analytical method development, release, and stability testing
- ✓ In-house cell line development capabilities if needed (Geneva, Switzerland)
- ✓ Mammalian and microbial expression systems

MilliporeSigma's Capabilities

- ✓ ADC & Bioconjugation from process development through GMP production for cytotoxic and non-cytotoxic projects
- ✓ Respective analytical method development, release, and stability testing
- ✓ Clinical and commercial development and manufacturing capabilities
- ✓ Internal site network for ADC payload-linker production and partnership for fill-finish



- KBI Biopharma facilities
- MilliporeSigma facilities

Integrated US-based ADC Offering

Together, we provide a seamless service package supporting customers from pre-clinical development through commercialization, backed by a US-based site network and a proven track record as industry-leading CDMOs.

Integrated Expertise. Accelerated Outcomes.



Integrated Program Teams

1. Industry-leading scientists working together from proposal to project
2. Existing governance and infrastructure to support organized and efficient delivery
3. Synergistic expertise and technical acumen from teams with a shared dedication to innovation



Optimized Timelines & Material Allocation

1. Strategic planning from proposal development with a focus on customer clinical and commercialization goals
2. Bespoke approach to each program with acceleration opportunities tailored to customer priorities
3. Proactive planning for optimized material usage, potentially rendering additional cost savings



Streamlined Vendor Management

1. Team integration enables reduced resource burden for customer external supply chain stakeholders
2. Cohesive presentation of data and timelines support faster decision-making
3. Domestic supply network from mAb development through bulk drug substance production minimizes logistical constraints

Let's Connect



Scan to learn more about KBI's analytical and manufacturing expertise and get in touch with our team



Scan to learn more about MilliporeSigma's ADC and bioconjugation capabilities and discuss your next project

